On 15 October, the Department of Health announced they have extended the shingles (herpes zoster) vaccine catch-up program available under the National Immunisation Program. The catch-up program offered to people aged 71-79 years was due to end on 31 October 2021, and has now been extended for a further 2 years to 31 October 2023. This program extension will allow those who missed or delayed vaccination due to pandemic restrictions or other reasons, extra time to get vaccinated with Zostavax® to protect against shingles disease.
Practices can automatically receive a monthly report of patients due and overdue for the Zostavax vaccine from Australian Immunisation Register (AIR). Email email@example.com for assistance with generating these recurring reports.
As Zostavax® is a live vaccine, it is contraindicated in some patients with immunocompromising conditions. It is important to review the latest guidance on herpes zoster in the Australian Immunisation Handbook and screen patients for contraindications using the screening tool in the Handbook.
Vaccination providers are also reminded that it is now mandatory to report all NIP vaccinations to the Australian Immunisation Register.
The Australian Government’s new International COVID-19 Vaccination Certificate provides secure and internationally recognised proof of their COVID-19 vaccination history. The international certificate features a Quick Response (QR) code, which is generated using the COVID-19 vaccination information in the Australian Immunisation Register and your passport details. Access your international certificate using either your Medicare online account through myGov, the Express Plus Medicare mobile app, or contact AIR on 1800 653 809.
You can get your international certificate when you’re getting ready to travel if all the following apply:
you have a current Australian passport or foreign passport with an Australian visa
you’ve had at least one dose of an approved COVID-19 vaccine
your vaccination provider has reported your COVID-19 vaccinations to the Australian Immunisation Register (AIR)
People who have had COVID-19 can be vaccinated with a COVID-19 vaccine once they have recovered from their illness. There is no need to delay vaccination, however it may be deferred for up to 6 months. This is because a past infection reduces the chances of getting COVID-19 again for at least this amount of time.
How will I know when I can leave self-isolation?
You have received a text message (SMS) or email which confirms the end of your isolation period. This is called your medical clearance notice. This means that you are no longer infectious and cannot pass COVID-19 on to other people. Please keep the SMS or email of your medical clearance notice with you when you leave home in case you need it to show your employer or NSW Police.
COVID-19 testing after isolation
After you are released from isolation, routine COVID-19 testing (such as workplace testing) is not required for six months. This is because tests for COVID-19 may continue to give a positive result for a while after infection, even though you are no longer infectious.
If practices are unable to relocate excess doses locally (contacted PHN and local practices), email the Vaccine Operations Centre (VOC) firstname.lastname@example.org for assistance. In some instances, the VOC may be able to arrange collection of excess doses for redistribution to another site. The VOC can only accept 20 vials or more of AstraZeneca; and 10 vials or more of Pfizer.
Proposed collection orders will be assessed for suitability, taking into consideration shelf life, time in transit, and clinic location. Practices will need to provide VOC with details about excess stock, including batch number, expiry date and number of excess doses, to be considered as part of this assessment. Once assessed, practices will receive a notification email confirming collection, or with disposal instructions.
If you have been unable to redirect your stock and the stock expires, please report the wastage through the COVID-19 Vaccine Administrative System (CVAS). Waste needs to be disposed of in accordance with the mandatory training, and vials must be disposed of in the provided sharps container to ensure they cannot be accessed.
AusVaxSafety has recently published their summary report which shows the percentage of reported adverse events, reported non-events, the percentage of those who saw a doctor or emergency department in the days after vaccination, and the most commonly reported events. The infographic also displays the vaccines given at each schedule point in 2020 and what diseases the vaccines protect against.
On 7 October 2021, enhancements were implemented to the Australian Immunisation Register (AIR) to remove the maximum dose number for the meningococcal B vaccine, Bexsero. Previously, the AIR only allowed a maximum of four doses to be reported for an individual. Vaccination providers can now report all Bexsero vaccines administered to an individual to the AIR, ensuring they have a complete immunisation record.
Join the latest COVID-19 vaccine live stream update for GPs. The panel will provide latest key updates and answer participants’ questions live about the COVID-19 vaccine rollout. Get involved by submitting questions and comments!
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: Are your vaccines ready for summer? In the summer season, storms are more likely to occur, which can lead to power outages. Refer to the Cold Chain Toolkit to ensure all vaccination storage requirements are in place should an outage occur. Disposal of Zostavax® Zostavax® vaccine will…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
NSW urged to prepare for heat wave Severe heatwave conditions are forecast in NSW in the coming days. Please read the NSW Health media release about taking steps to prevent heat-related illness. For further information about staying safe in a heatwave, visit Beat the heat and stay well during hot…